Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination
(2013) In Allergy 68(9). p.1136-1142- Abstract
- BackgroundThis placebo-controlled study assessed the effects of the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2)-agonist (LABA) vilanterol (VI) on early and late asthmatic responses (EAR/LAR) and airway hyper-responsiveness (AHR). MethodsPatients (n=27) were randomized to FF (100g), VI (25g), FF/VI (100/25g), and placebo for 21days (four periods). Allergen challenge was performed 1h post-dose on day 21. AHR was assessed on day 22 using methacholine. ResultsAllergen challenge caused an early change (0-2h) in minimum forced expiratory volume in 1s (FEV1) of -1.091l (95% CI: -1.344; -0.837) following placebo therapy; changes were -0.955l (-1.209; -0.702), -0.826l (-1.070; -0.581), and -0.614l... (More)
- BackgroundThis placebo-controlled study assessed the effects of the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2)-agonist (LABA) vilanterol (VI) on early and late asthmatic responses (EAR/LAR) and airway hyper-responsiveness (AHR). MethodsPatients (n=27) were randomized to FF (100g), VI (25g), FF/VI (100/25g), and placebo for 21days (four periods). Allergen challenge was performed 1h post-dose on day 21. AHR was assessed on day 22 using methacholine. ResultsAllergen challenge caused an early change (0-2h) in minimum forced expiratory volume in 1s (FEV1) of -1.091l (95% CI: -1.344; -0.837) following placebo therapy; changes were -0.955l (-1.209; -0.702), -0.826l (-1.070; -0.581), and -0.614l (-0.858; -0.370) following VI, FF, or FF/VI therapy, respectively. Treatment differences were significant for all comparisons between therapies. Mean changes in 0-2h%FEV1 were as follows: -28.05 (placebo), -23.10 (VI), -22.33 (FF), and -16.10 (FF/VI). Following placebo, the late change (4-10h) in weighted mean FEV1 was -0.466l (-0.589; -0.343) and -0.298l (-0.415; -0.181) after VI, and was +0.018l with both FF/VI (-0.089; 0.124) and FF (-0.089; 0.125). Treatment differences were significant for all comparisons between therapies except FF/VI vs FF. Mean changes in 4-10h%FEV1 were as follows: -21.08 (placebo), -14.30 (VI), -5.02 (FF), and -5.83 (FF/VI). AHR 24h after allergen challenge was significantly reduced with FF/VI and FF vs placebo, and FF/VI was superior to either component. ConclusionCombined treatment with FF/VI provides additive protection from the EAR relative to its components, significant protection over VI alone from the LAR, and confers sustained protection from hyper-responsiveness 24h post-dose. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4172206
- author
- Oliver, A. ; Bjermer, Leif LU ; Quinn, D. ; Saggu, P. ; Thomas, P. ; Yarnall, K. and Loetvall, J.
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- allergen challenge, asthma, atopy, inhaled corticosteroid, long-acting, beta(2)-agonist
- in
- Allergy
- volume
- 68
- issue
- 9
- pages
- 1136 - 1142
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000324931500006
- scopus:84884985589
- pmid:23924233
- ISSN
- 1398-9995
- DOI
- 10.1111/all.12205
- language
- English
- LU publication?
- yes
- id
- 65d7d27a-f3d3-4659-95e4-4f40d727bdca (old id 4172206)
- date added to LUP
- 2016-04-01 14:57:32
- date last changed
- 2022-01-28 03:21:02
@article{65d7d27a-f3d3-4659-95e4-4f40d727bdca,
abstract = {{BackgroundThis placebo-controlled study assessed the effects of the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta(2)-agonist (LABA) vilanterol (VI) on early and late asthmatic responses (EAR/LAR) and airway hyper-responsiveness (AHR). MethodsPatients (n=27) were randomized to FF (100g), VI (25g), FF/VI (100/25g), and placebo for 21days (four periods). Allergen challenge was performed 1h post-dose on day 21. AHR was assessed on day 22 using methacholine. ResultsAllergen challenge caused an early change (0-2h) in minimum forced expiratory volume in 1s (FEV1) of -1.091l (95% CI: -1.344; -0.837) following placebo therapy; changes were -0.955l (-1.209; -0.702), -0.826l (-1.070; -0.581), and -0.614l (-0.858; -0.370) following VI, FF, or FF/VI therapy, respectively. Treatment differences were significant for all comparisons between therapies. Mean changes in 0-2h%FEV1 were as follows: -28.05 (placebo), -23.10 (VI), -22.33 (FF), and -16.10 (FF/VI). Following placebo, the late change (4-10h) in weighted mean FEV1 was -0.466l (-0.589; -0.343) and -0.298l (-0.415; -0.181) after VI, and was +0.018l with both FF/VI (-0.089; 0.124) and FF (-0.089; 0.125). Treatment differences were significant for all comparisons between therapies except FF/VI vs FF. Mean changes in 4-10h%FEV1 were as follows: -21.08 (placebo), -14.30 (VI), -5.02 (FF), and -5.83 (FF/VI). AHR 24h after allergen challenge was significantly reduced with FF/VI and FF vs placebo, and FF/VI was superior to either component. ConclusionCombined treatment with FF/VI provides additive protection from the EAR relative to its components, significant protection over VI alone from the LAR, and confers sustained protection from hyper-responsiveness 24h post-dose.}},
author = {{Oliver, A. and Bjermer, Leif and Quinn, D. and Saggu, P. and Thomas, P. and Yarnall, K. and Loetvall, J.}},
issn = {{1398-9995}},
keywords = {{allergen challenge; asthma; atopy; inhaled corticosteroid; long-acting; beta(2)-agonist}},
language = {{eng}},
number = {{9}},
pages = {{1136--1142}},
publisher = {{Wiley-Blackwell}},
series = {{Allergy}},
title = {{Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination}},
url = {{http://dx.doi.org/10.1111/all.12205}},
doi = {{10.1111/all.12205}},
volume = {{68}},
year = {{2013}},
}